On the basis of a coverage decision for anti-amyloid monoclonal antibodies recently issued by the US Centers for Medicare and Medicaid Services, Medicare will offer ‘coverage with evidence development’ to allow more information on the clinical benefits of these antibodies to be gathered. Here, we discuss the implications of this decision for future clinical trials and Alzheimer disease care.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Liu, K. Y. & Howard, R. Can we learn lessons from the FDA’s approval of aducanumab? Nat. Rev. Neurol. 17, 715–722 (2021).
Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&ncaid=305 (Centers for Medicare and Medicaid Services, 2022).
Day, G. S. et al. Aducanumab use in symptomatic Alzheimer disease evidence in focus: a report of the AAN Guidelines Subcommittee. Neurology 98, 619–631 (2022).
Cummings, J. et al. Aducanumab: appropriate use recommendations. J. Prev. Alzheimers Dis. 8, 398–410 (2021).
Hlavka, J. P., Mattke, S. & Liu, J. L. Assessing the preparedness of the health care system infrastructure in six European countries for an Alzheimer’s treatment. Rand Health Q. 8, 2 (2019).
Biogen Submits Final Protocol for ADUHELM® (aducanumab-avwa) Phase 4 ENVISION Trial to FDA https://investors.biogen.com/news-releases/news-release-details/biogen-submits-final-protocol-aduhelmr-aducanumab-avwa-phase-4 (Biogen, 2022).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
D.K. serves on a Data Safety Monitoring Board (DSMB) for the Dominantly Inherited Alzheimer Network (DIAN) study. He served on a data safety monitoring board for a tau therapeutic for Biogen but received no personal compensation. He is an investigator in clinical trials sponsored by Biogen, Lilly Pharmaceuticals and the University of Southern California. He has served as a consultant for Roche, Samus Therapeutics, Magellan Health and Alzeca Biosciences but receives no personal compensation. He receives funding from the NIH. M.S. serves as a consultant for Eisai, Avenir, vTv, Biogen, BioXcel, Hoffman LaRoche, NovoNordisk, Novartis and Merck. She chairs the DSMB for the Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer’s Disease (SESAD), sponsored by the University of Colorado. She receives funding from the NIH. H.H.F. serves as a member of a DSMB/Data Monitoring Committee for Janssen Research and Development and the Roche/Banner Institute, for which he does not receive personal compensation. He receives grant funding through the University of California San Diego (UCSD) from Biohaven Pharmaceuticals, Annovis (QR Pharma), AC Immune, Vivoryon (Probiodrug) and LuMind Foundation and has service agreements for consulting through UCSanD with Novo Nordisk, Samus Therapeutics, Samumed, Tau Consortium & Rainwater Charitable Foundation and Axon Neurosciences, for which he does not receive personal compensation. He holds grant funding from the NIH and the Canadian Institutes of Health Research.
Rights and permissions
About this article
Cite this article
Knopman, D., Sano, M. & Feldman, H.H. CMS coverage decision on anti-amyloid monoclonal antibodies for Alzheimer disease. Nat Rev Neurol 18, 379–380 (2022). https://doi.org/10.1038/s41582-022-00672-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41582-022-00672-3
